Women's Health

Hair loss on GLP-1s: what the 2026 evidence actually shows

By the US Health Digest editorial team · Published August 26, 2026 · Every claim linked to its primary source

A study published in The BMJ on July 22, 2026 found that adults with type 2 diabetes who started a GLP-1 receptor agonist had more clinically recorded hair loss than adults who started two comparator diabetes drugs — hazard ratio 1.37 (95% CI 1.08 to 1.73) versus SGLT-2 inhibitors and 1.68 (1.28 to 2.20) versus DPP-4 inhibitors. The absolute numbers are small: 6.91 versus 5.04 adjusted diagnoses per 1,000 person-years, roughly two extra a year per 1,000 people. It is observational, so it estimates association, not cause, and the authors' leading explanation is the weight loss, not the molecule. The sharpest signal for women is not in that paper: it is on the labels, where Zepbound reports hair loss in "7.1% female versus 0.5% male" patients across its two pivotal trials.

What the BMJ study actually did

It is a target trial emulation: an observational design that writes out the randomised trial it wishes it could run, then emulates that protocol in real-world records — here, Penn Medicine electronic health records, January 2019 to September 2024. The population was adults with type 2 diabetes newly starting a drug, not people taking a GLP-1 for weight loss alone; anyone with an alopecia diagnosis in the year before their first prescription was excluded, along with anyone who had used a competing glucose-lowering drug class in that year.

The comparators matter: rather than users versus non-users, the authors used two active comparators, SGLT-2 inhibitors and DPP-4 inhibitors, which is the study's main defence against confounding by indication. Cohorts were 12,004 GLP-1 initiators against 15,221 SGLT-2 inhibitor initiators, and 11,964 against roughly 11,200 DPP-4 inhibitor initiators. The outcome was any alopecia diagnosis code, which caps what can be seen: the findings "primarily reflect clinically documented, healthcare seeking cases of alopecia rather than the full spectrum of disease in the underlying population, which may be higher." Events peaked just before 12 months.

The relative number and the absolute number

Both belong in the same sentence. Most coverage carried only the first.

• Versus SGLT-2 inhibitors: adjusted incidence 6.91 versus 5.04 per 1,000 person-years; hazard ratio 1.37 (95% CI 1.08 to 1.73) — about 1.9 extra recorded diagnoses per 1,000 people a year.
• Versus DPP-4 inhibitors: 6.53 versus 3.89 per 1,000 person-years; hazard ratio 1.68 (1.28 to 2.20) — about 2.6 per 1,000 a year.
• By subtype: the association sat in non-scarring alopecia — 1.53 (1.18 to 1.97) and 1.72 (1.28 to 2.31) — with no clear association for alopecia areata, the autoimmune form, "which does not support a predominant autoimmune mechanism in this setting."

The abstract flags "attenuation after negative control outcome calibration," a bias check across 30 outcomes the drug could not plausibly cause. E values were 2.08 and 2.75 — the minimum strength an unmeasured confounder would need, with both the drug and the outcome, to explain the result away entirely; the lower bounds of the confidence intervals corresponded to E values of 1.37 and 1.88. The authors read that as "moderate robustness to unmeasured confounding."

Three published analyses, three different measures

One caution: the subtype figures the meta-analysis reports at 12 months are the same point estimates Vidal and colleagues published, so the rows overlap and are not three independent confirmations. Database work here is contested — a separate TriNetX analysis (PMID 41825835) drew a published "Methodological Concerns" letter in August 2026, to which its authors published a response the same month. We take no position on that exchange.

What the labels say, and how they split it by sex

Here the evidence gets specific about women, and it is randomised trial data rather than database data. Neither current label uses the word "alopecia"; both use "Hair Loss," and on both it sits in Adverse Reactions and the patient information only — not in Warnings and Precautions.

The current Wegovy label (SPL version 19, effective June 18, 2026) states: "Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction. In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male)." That pool is three placebo-controlled trials: 2,116 adults on 2.4 mg, 71% female, against 1,261 on placebo. At 7.2 mg the same section reports "5.8% ... (8.4% female, 0.2% male)" against "1.0% of patients on placebo (1.5% female, 0 male)."

The current Zepbound label (SPL version 38, effective April 22, 2026) reports hair loss in 1% on placebo versus 5%, 4% and 5% at 5, 10 and 15 mg (placebo n=958; 630, 948 and 941 by dose), and adds: "hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss." Of the 2,519 adults given Zepbound, 37% were male; the label does not print the female denominator.

These are investigator-reported adverse-event terms, and each product's own placebo group is the only fair comparison: the programmes used different trials, populations and durations, so the percentages are not a head-to-head result. What survives is the direction: women reported it several times more often than men, and placebo groups reported it too.

The competing explanation: telogen effluvium

Rapid weight loss triggers hair shedding whether or not a drug is involved. Telogen effluvium is "the excessive shedding of resting or telogen hair after some metabolic stress, hormonal changes, or medication," with triggers including major surgery, severe illness, postpartum hormonal change, crash dieting, low protein intake and iron deficiency. Stress pushes growing hairs into the resting phase early; the shed becomes visible only when those hairs are pushed out months later.

The timeline is the tell. The same reference puts the trigger "approximately 3 months before the onset of the shedding," range 1 to 6 months, notes that acute shedding "lasts less than 6 months" by definition, that "acute telogen effluvium is a self-limited condition," and that "hair growth may take up to 6 months to restart and even longer for the growth to be appreciated by the patient." For scale, a normal scalp holds about 100,000 hairs and sheds roughly 50 to 200 a day. That lag is why shedding often surfaces in month three or four, when weight loss is steepest.

In a single-centre series of 140 people with weight-loss-associated telogen effluvium — 110 women and 30 men, mean age 34.6 — mean weight loss was 15.2% at 3.5 kg a month, and the women developed it at a significantly slower rate of loss than the men (3.14 versus 5.03 kg a month, p=0.026). The authors conclude that women and older adults are especially vulnerable "even if the degree of weight loss is not more severe than in men and young adults." There was no control group, and the cases were collected between June 2006 and March 2021, before the current GLP-1 weight-loss wave: it describes the phenomenon, not the drug. The BMJ authors land in the same place — "hair loss may reflect downstream effects of metabolic change rather than a direct drug effect." One detection issue is worth naming: the dermatology literature records that women are "more likely to seek medical attention" for shedding than men, and a study built on diagnosis codes counts only those who sought care. See also what fast weight loss does to lean mass.

The commercial layer

Two supplement companies have registered trials in exactly this population. NCT07484061, from Olistic Research Labs S.L. with a Madrid dermatology group, is a randomised, double-blind, placebo-controlled study of 40 women over 35 starting a GLP-1/GIP agonist, over 180 days, primary outcome a patient-reported shedding scale. Its registry text describes the drink as "vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45" — a company describing its own product, not a finding. NCT07783113, from Farmoquimica S.A. in Brazil, carries less weight still: 48 women, single group, no control arm, no masking, not yet recruiting.

Neither has posted results, and no published randomised trial supports any supplement for hair loss in GLP-1 users. Supplements are not reviewed for effectiveness before sale: the FDA states manufacturers "are responsible for evaluating the safety and labeling of their products before marketing," with the agency acting only "after it reaches the market." The FTC's Gut Check guide exists because that gap gets filled with claims. Traffic is not all one way: NCT07734870, a Johns Hopkins open-label pilot in 20 participants — listing Eli Lilly, which makes tirzepatide, among its collaborators — is testing tirzepatide as a treatment for a scarring alopecia. It has no control group either.

Questions for your prescriber or dermatologist

This is evidence reporting, not medical advice. Nothing here is a reason to start, stop or change a medication.

• When did the shedding start relative to the weight loss, and how fast has the weight been falling?
• Is this diffuse shedding, or patchy or scarring loss? Different conditions, different workups.
• Should we check ferritin, iron saturation, thyroid function or protein intake?
• Is a dermatology referral appropriate, and what would a pull test or trichoscopy add?
• If this is telogen effluvium, what timeline is realistic, and what would make you rethink the diagnosis?

The BMJ authors suggest clinicians "consider discussing the possibility of hair loss when initiating GLP-1 receptor agonist therapy and monitoring for symptoms during follow-up, particularly in the first year." See also GLP-1 side effects in women, GLP-1s after 40, stopping and regain and our GLP-1 FAQ.

What we could not establish

The BMJ paper pre-specified sex as a subgroup, but the sex-specific hazard ratios appear only inside its forest-plot figures — not in the text, tables or the 22-page supplement — and we will not read numbers off a plot. The text says subgroup analyses stratified by age, sex and nine other variables "showed generally consistent associations across strata," with evidence of effect modification only for metformin use (P=0.02, versus SGLT-2 inhibitors) and race and ethnicity (P=0.03, versus DPP-4 inhibitors) — not sex. The strongest sex-stratified numbers here are therefore the label frequencies, not the study. We also found no trial with hair loss as a pre-specified endpoint, no published estimate of how much of the association weight loss mediates, and no severity or recovery data in the three analyses above.

Sources

1. Tang H, Zhang B, Lu Y, Zhang D, Liu R, Lu Y, Cotsarelis G, Asch DA, Chen Y. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. PubMed 42486607. Open access under CC BY; doi 10.1136/bmj-2026-100077. Full text, figures and 22-page data supplement consulted.
2. DailyMed. WEGOVY (semaglutide) injection and tablet — current prescribing information. National Library of Medicine; SPL version 19, effective June 18, 2026. Adverse Reactions section 6.1, "Hair Loss," and Tables 3, 4 and 5.
3. DailyMed. ZEPBOUND (tirzepatide) injection — current prescribing information. National Library of Medicine; SPL version 38, effective April 22, 2026. Adverse Reactions section 6.1, "Hair Loss," and Table 1.
4. Vidal SI, Akiska YM, Nasseri M, et al. Increased risk of hair loss with GLP-1 receptor agonists: a real-world multicenter TriNetX cohort study. JAAD International. 2026;25:133-135. Open-access full text (PubMed Central).
5. Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disorders. 2026. PubMed 42621629.
6. Lauck KC, Ahmed A, Tolkachjov SN. Alopecia after glucagon-like peptide-1 agonist therapy: a TriNetX Database active comparator retrospective cohort study. Journal of the American Academy of Dermatology. 2026;95(1):238-240. PubMed 41825835. See also the correspondence: Jean SS, Lai CC. Methodological Concerns Regarding "Alopecia after GLP-1 Agonist Therapy…", PubMed 42641691 (online August 25, 2026), and the original authors' reply, Lauck KC, Ahmed A, Tolkachjov SN, PubMed 42637046 (online August 24, 2026).
7. Hughes EC, Syed HA, Saleh D. Telogen Effluvium. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; last updated May 1, 2024. NCBI Bookshelf NBK430848, National Library of Medicine.
8. Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Annals of Dermatology. 2024;36(6):384-388. PubMed 39623615.
9. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. Journal of the American Academy of Dermatology. 2025;92(5):1141-1143. PubMed 39863171.
10. Santiago Mangual KP, Midura I, Patin E, et al. Aesthetic, muscle, and dermatologic effects of medical weight management: patient-reported outcomes shape a holistic preventive procedural approach. International Journal of Women's Dermatology. 2026;12(3):e283. PubMed 42639588.
11. National Library of Medicine. Hair loss. MedlinePlus Medical Encyclopedia.
12. ClinicalTrials.gov registry records: NCT07484061 (Olistic Research Labs S.L.; drinkable nutraceutical; 40 women; randomised, double-blind, placebo-controlled; recruiting since March 16, 2026); NCT07783113 (Farmoquimica S.A.; dietary supplement; 48 women; single group, no masking; not yet recruiting); NCT07734870 (Johns Hopkins University; tirzepatide for central centrifugal cicatricial alopecia; phase 2, open label, n=20; not yet recruiting).
13. U.S. Food and Drug Administration. Dietary Supplements — manufacturer responsibilities and FDA's post-market authority.
14. Federal Trade Commission. Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims.